J&J says booster shot vastly increases antibody

Johnson and Johnson is touting the benefits of a booster dose for its single-shot vaccine.

The company revealed Wednesday that the extra shot of its COVID-19 vaccine resulted in antibody levels that were nine times higher compared with those who received the one dose.

The results were part of interim data from two early-stage trials. J&J says full results will be released in coming weeks.

Up until now there had been no evidence about the effect of a booster dose of the J&J vaccine.

Advisers for the U.S. Centers for Disease Control and Prevention had been waiting for word on how to advise immunocompromised individuals who received the J&J vaccine.

According to a press release from J&J, studies show significant increases in binding antibody responses, which means the body's white blood cells join in to fight off COVID-19, in participants aged 18-55.

Those 65 years and older also saw a meaningful response when given a lower booster dose.

J&J said it is working with the CDC, the U.S. Food and Drug Administration, the European Medicines Agency, the World Health Organization and other health authorities about delivering the J&J booster shot.

Despite the convenience of the one-dose vaccine, compared to two doses for Pfizer-BioNtech and Moderna, the J&J shot has had the lowest use rate in Europe of all the approved inoculations, and lags in the U.S. as well due to safety concerns and manufacturing stumbles.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting